Clinical trial
Bevacizumab and Radiation Therapy for Sarcomas
NCT00356031 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00356031 |
|---|---|
| Title | Bevacizumab and Radiation Therapy for Sarcomas |
| Official title | A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Institutes of Health (NIH) NIH National Cancer Institute (NCI) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Soft Tissue Sarcoma, Fibrous Histiocytoma, Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Synovial Sarcoma |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | Bevacizumab, Radiation Therapy, Surgery |
| Enrollment | 20 |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Jul 25, 2006 |
| Last update posted | May 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: